← Back to patent-cliff list
HS-10506
Tier C — Watch / tradeHS-10506
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：OX2R
Indications (approved)：Insomnia and sleep disorders, Depressive disorder
Regional status
US
-
EU
-
China
Phase III
2026-04-24
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of HS-10506?
Approved indications include: Insomnia and sleep disorders, Depressive disorder.
When does the HS-10506 patent expire?
No public expiry year is available for HS-10506 yet; this page updates once verified.
How do I get a quote for HS-10506 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29